Protalix BioTherapeutics, Inc. (PLX)

↓ Download CSV

CIK 0001006281 · NYSE · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Protalix BioTherapeutics, Inc. reported revenue of $52.74M, down 1.2% from the prior year. The company ran a net loss, with a net margin of -12.5%. It held $82.35M in total assets against $34.12M in total liabilities.

Key ratios (FY2025)

-10.4%
Operating margin
-12.5%
Net margin
-13.7%
Return on equity
-1.2%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$52.74M$53.40M$65.49M$47.64M$38.35M$62.90M$54.69M$34.24M$21.08M$9.20M
Cost of Revenue$26.99M$24.32M$22.98M$19.59M$16.35M$10.87M$10.89M$9.30M$15.23M$8.40M
Gross Profit$4.01M$801.0K
Operating Income-$5.50M$3.92M$10.46M-$13.01M-$20.46M$2.71M-$10.72M-$19.31M-$34.52M-$33.16M
Net Income-$6.60M$2.93M$8.31M-$14.93M-$27.58M-$6.52M-$18.28M-$26.46M-$83.44M-$29.36M
EPS (Diluted)$-0.08$0.04$0.09$-0.31$-0.62$-0.22$-1.23
Total Assets$82.35M$73.42M$84.43M$55.79M$73.67M$67.93M$45.39M$61.13M$72.21M$82.25M
Total Liabilities$34.12M$30.21M$50.87M$66.43M$79.70M$94.97M$115.71M$114.01M$101.67M$92.20M
Shareholders' Equity$48.23M$43.21M$33.57M-$10.64M-$6.04M-$27.04M-$70.32M-$52.88M-$29.46M-$9.96M
Cash & Equivalents$14.68M$19.76M$23.63M$17.11M$38.98M$18.27M$17.79M$37.81M$51.16M$63.28M
Operating Cash Flow-$11.99M$8.67M-$1.32M-$25.00M-$10.29M-$26.11M-$19.36M-$7.74M-$9.99M-$32.10M
Capital Expenditures$1.64M$1.28M$1.15M$628.0K$1.46M$655.0K$627.0K$686.0K$971.0K$849.0K
Shares Outstanding80.43M75.85M72.95M53.79M45.56M34.77M14.84M14.84M143.73M124.13M